DOCSLIB.ORG

API and Working Standards for Pharmaceutical Quality Control

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
API and Working Standards for Pharmaceutical Quality Control API and working standards for pharmaceutical quality control Special OFFER Ends 30 June 2017 ISO 9001 • ISO/IEC 17025 • ISO Guide 34 • GMP/GLP • ISO 13485 • ISO/IEC 17043 LGC Quality ‒ Great savings on API Offer only available reference standards until 30 June 2017! We are offering more than 650 selected API reference standards at reduced prices. They are available as single Order online and enter for the units or multi packs of 5 or more units. chance to win an iPad at Our API standards come with a certificate of analysis www.lgcstandards.com/APIspecialoffer (CoA) including a very detailed identity section and assay determination by the 100 % method. Check out the alphabetical product listing on page 4. View detailed sample certificate 2 Let us help you save time. Our working standards Get your individual working full service includes: standards from LGC • Qualification of your material or the material we have sourced for you, according to your We also provide API reference standards as working requirements. standards in high volumes for your daily routine measurements. • Qualification as primary working standard and when required additional comparison to a pharmacopoeial We have more than 30 years of experience of reference standard. helping our key customers in the production of bespoke working standards. • Packaging of materials into unit sizes most convenient for you, for example single-use vials. Our working standards are primary reference materials according to ISO Guide 34, and are • Alarm-controlled storage. available as single use vials in six different unit sizes • Regular shipping as per your individual schedule, from 100 mg - 5 g. Assay determination on the final or all at once. sales units alongside with homogeneity and stability • Stress testing and regular stability monitoring. testing ensure the highest levels of quality. • Valid vials and certificates constantly available. Try our working standards service to understand how you can save time and improve efficiency in your laboratory. Get a quote here If you would like to discuss how to save time by using our working standards call your local LGC Standards office or receive a quote direct from our website. 3 Click on product code to order now Product name Classification Product code Unit size [mg] Acecarbromal API MM1724.00 50 Acefylline API MM1727.00 250 Acenocoumarol API MM1205.00 250 Acepromazine Maleate API MM0927.00 250 Acetaminosalol API MM1609.00 250 Acetazolamide API MM0648.00 500 Acetomenaphthone (Menadiol Diacetate) API MM1730.00 250 Acetophenazine Maleate API MM1725.00 100 Acitretin API MM3427.00 250 Adefovir Dipivoxil API MM3505.00 250 Adenosine API MM0784.00 500 Adiphenine Hydrochloride API MM1172.00 250 β-Alanine (3-Aminopropanoic Acid) API MM1463.01 100 Alclofenac API MM1783.00 100 Allantoin API MM1627.00 250 Alprostadil API MM1553.00 50 Ambutonium Bromide API MM1780.00 100 Amfetamine Hydrochloride API MM0741.06 100 Amfetamine Sulfate API MM0741.00 100 Aminitrozole API MM1745.00 100 Aminocaproic Acid API MM0896.00 500 Aminoglutethimide API MM1777.00 250 Amiquinsin Hydrochloride Monohydrate API MM3280.00 50 Amisometradine API MM1751.00 50 Amobarbital API MM1353.00 100 Amodiaquine Dihydrochloride Dihydrate API MM0617.00 500 Amotriphene Hydrochloride API MM3021.00 50 Amoxapine API MM1773.00 100 Ampicillin Trihydrate API MM0253.15 500 Amprolium Hydrochloride API MM1772.00 250 Amylmetacresol API MM1132.00 250 Anastrozole API MM1250.00 250 Antazoline Phosphate API MM0561.00 500 Arginine Aspartate (L-Arginine L-Aspartate) API MM3575.00 250 4 Find more reference standards at www.lgcstandards.com 2017 Find more reference standards at www.lgcstandards.com Click on product code to order now Product name Classification Product code Unit size [mg] Artemether API MM3252.00 250 Articaine Hydrochloride API MM0369.00 250 Aspartame Excipient MM0314.00 500 Atomoxetine Hydrochloride API MM1304.00 250 Atovaquone API MM3007.00 250 Atracurium Besilate API MM0858.00 250 Avanafil API MM3313.00 100 Azaperone API MM1164.00 250 Azathioprine API MM1532.00 250 Baclofen API MM1235.00 250 Bambuterol Hydrochloride API MM0773.00 100 Bamethan Sulfate API MM1822.00 100 Bamifylline Hydrochloride API MM1823.00 100 Barbital API MM1721.00 100 Barbital Sodium API MM1652.00 100 Bazedoxifene Acetate API MM3342.00 50 Beclamide API MM1825.00 100 Bemegride API MM1747.00 100 Benactyzine Hydrochloride API MM1826.00 100 Benazepril Hydrochloride API MM1229.00 100 Bendroflumethiazide API MM0674.00 100 Benorilate API MM0399.00 100 Benzbromarone API MM0456.00 500 Benzthiazide API MM1716.00 50 Benzylpenicillin Procaine API MM0302.00 250 Bephenium Embonate API MM1833.00 50 Bephenium Hydroxynaphthoate API MM1832.00 100 Berberine Chloride API MM1632.00 250 Berberine Hemisulfate API MM3304.00 250 Betaine Hydrochloride API MM0611.00 500 Betaxolol Hydrochloride API MM0436.00 250 Bethanechol Chloride API MM1634.00 250 Bibenzonium Bromide API MM1835.00 100 Biphenamine Hydrochloride API MM1877.00 100 Find more reference standards at www.lgcstandards.com 2017 Find more reference standards at www.lgcstandards.com 5 Click on product code to order now Product name Classification Product code Unit size [mg] Bis(2-ethylhexyl) Maleate Chemical MM2104.00 250 Bitoscanate API MM1837.00 250 Boldine API MM3308.01 100 Bosentan Monohydrate API MM3369.00 250 Bromfenac Sodium Sesquihydrate API MM3532.00 250 Brotizolam API MM1443.00 250 Broxyquinoline API MM1841.00 250 Buflomedil Hydrochloride API MM0066.00 500 Buformin Hydrochloride API MM1843.00 100 Buprenorphine API MM0120.00 100 Buprenorphine Hydrochloride API MM1237.00 250 Buspirone Hydrochloride API MM0464.00 500 Butacaine Sulfate API MM1638.00 250 Butalamine Hydrochloride API MM1845.00 50 Butamben API MM1802.00 250 Butobarbital API MM1625.00 100 Butoconazole Nitrate API MM1637.00 250 Butylene Glycol (Butane-1,3-diol) API MM0839.00 250 Caffeine Citrate API MM1851.00 250 Calcium Folinate API MM0324.00 250 Calcium Pantothenate API MM1499.00 250 D-Camphor API MM3327.00 250 Camphor, Racemic API MM0103.00 250 Canadine API MM3085.00 100 Cantharidin API MM2534.00 100 Capecitabine API MM0992.00 100 Caprylic Acid API MM3387.00 250 Captodiame Hydrochloride API MM1853.00 50 Caramiphen Hydrochloride API MM1585.00 50 Carbachol API MM1711.00 250 Carbamazepine API MM0076.00 250 Carbinoxamine Maleate API MM1135.00 50 Cefaclor Monohydrate API MM0326.00 100 Cefadroxil Monohydrate API MM0972.00 250 6 Find more reference standards at www.lgcstandards.com 2017 Find more reference standards at www.lgcstandards.com Click on product code to order now Product name Classification Product code Unit size [mg] Cefalexin Monohydrate API MM0605.00 500 Cefalonium Dihydrate API MM3169.00 250 Cefepime Dihydrochloride Monohydrate API MM1475.00 250 Cefixime Trihydrate API MM0316.00 250 Cefotaxime Sodium API MM0414.00 250 Cefoxitin Sodium API MM1858.00 250 Cefradine API MM0833.00 250 Ceftiofur API MM3577.00 250 Cefuroxime Sodium API MM1341.00 250 Celecoxib API MM0344.00 100 Chloral Betaine API MM1752.00 100 Chloralose API MM2538.00 250 Chlorcyclizine Hydrochloride API MM1653.00 100 Chlordiazepoxide API MM0028.08 100 Chlormadinone Acetate API MM0529.00 100 Chloroxylenol Excipient MM1997.00 250 Chlorphenoxamide API MM1990.00 100 Chlorphenoxamine Hydrochloride API MM1291.00 100 Chlorphentermine Hydrochloride API MM1742.00 100 Chlorpropamide API MM1635.00 250 Chlorprothixene Hydrochloride API MM1321.00 250 Chlorzoxazone API MM0908.00 250 Ciclesonide API MM3608.00 100 Cilastatin Sodium API MM1092.00 250 Cinoxacin API MM1991.00 100 Clemastine Fumarate API MM1444.00 250 Clenbuterol Hydrochloride API MM1299.00 250 Clidinium Bromide API MM1798.00 100 Clindamycin Palmitate Hydrochloride API MM1989.00 250 Clobetasone Butyrate API MM0207.00 250 Clobutinol Hydrochloride API MM0038.00 100 Clofazimine API MM1988.00 250 Clofibrate API MM1934.00 250 Clomethiazole Edisylate API MM1866.00 100 Find more reference standards at www.lgcstandards.com 2017 Find more reference standards at www.lgcstandards.com 7 Click on product code to order now Product name Classification Product code Unit size [mg] Clonazepam API MM0945.00 100 Cloponone API MM1987.00 50 Clorgyline Hydrochloride API MM3019.00 50 Clorindione API MM3020.00 50 Clorprenaline Hydrochloride API MM0716.02 250 Clorsulon API MM1518.00 250 Cloxacillin Sodium Monohydrate API MM0682.00 500 Cloxiquine API MM0391.00 500 Cocaine Hydrochloride API MM1345.00 100 Conivaptan Hydrochloride API MM3580.00 250 Coumatetralyl API MM3018.00 100 Cyclamic Acid API MM0678.05 100 Cyclandelate API MM0497.00 250 Cyclizine Hydrochloride API MM1265.00 250 Cyclofenil API MM3024.00 250 Cycloguanil Embonate API MM3025.00 50 Cycloguanil Hydrochloride API MM1580.00 100 Cyclopentobarbital API MM1579.00 50 Cyclopentolate Hydrochloride API MM0580.00 500 Cyclophosphamide Monohydrate API MM0822.00 250 Cycloserine API MM3028.00 250 Cyclothiazide API MM3047.00 100 Cycrimine Hydrochloride API MM3046.00 100 Cyproheptadine Hydrochloride Sesquihydrate API MM0609.00 500 Cytarabine API MM1117.00 250 Dacarbazine API MM1289.00 100 Danofloxacin Mesilate API MM3710.00 250 Dantrolene Sodium Hydrate API MM3086.00 250 Deanol Excipient MM1681.02 100 Deanol Acetamidobenzoate API MM1681.00 100 Debrisoquin Sulfate API MM0594.00 100 Decamethonium Iodide API MM3044.00 250 Decoquinate API MM3043.00 100 Demecarium Bromide API MM3042.00 100 8 Find more reference standards at www.lgcstandards.com 2017 Find more reference standards at www.lgcstandards.com Click on product code to order now Product name Classification Product
Load more

Recommended publications
  • Muscarinic Acetylcholine Receptor
    mAChR Muscarinic acetylcholine receptor mAChRs (muscarinic acetylcholine receptors) are acetylcholine receptors that form G protein-receptor complexes in the cell membranes of certainneurons and other cells. They play several roles, including acting as the main end-receptor stimulated by acetylcholine released from postganglionic fibersin the parasympathetic nervous system. mAChRs are named as such because they are more sensitive to muscarine than to nicotine. Their counterparts are nicotinic acetylcholine receptors (nAChRs), receptor ion channels that are also important in the autonomic nervous system. Many drugs and other substances (for example pilocarpineand scopolamine) manipulate these two distinct receptors by acting as selective agonists or antagonists. Acetylcholine (ACh) is a neurotransmitter found extensively in the brain and the autonomic ganglia. www.MedChemExpress.com 1 mAChR Inhibitors & Modulators (+)-Cevimeline hydrochloride hemihydrate (-)-Cevimeline hydrochloride hemihydrate Cat. No.: HY-76772A Cat. No.: HY-76772B Bioactivity: Cevimeline hydrochloride hemihydrate, a novel muscarinic Bioactivity: Cevimeline hydrochloride hemihydrate, a novel muscarinic receptor agonist, is a candidate therapeutic drug for receptor agonist, is a candidate therapeutic drug for xerostomia in Sjogren's syndrome. IC50 value: Target: mAChR xerostomia in Sjogren's syndrome. IC50 value: Target: mAChR The general pharmacol. properties of this drug on the The general pharmacol. properties of this drug on the gastrointestinal, urinary, and reproductive systems and other… gastrointestinal, urinary, and reproductive systems and other… Purity: >98% Purity: >98% Clinical Data: No Development Reported Clinical Data: No Development Reported Size: 10mM x 1mL in DMSO, Size: 10mM x 1mL in DMSO, 1 mg, 5 mg 1 mg, 5 mg AC260584 Aclidinium Bromide Cat. No.: HY-100336 (LAS 34273; LAS-W 330) Cat.
    [Show full text]
  • Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017
    Q UO N T FA R U T A F E BERMUDA PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 BR 111 / 2017 The Minister responsible for health, in exercise of the power conferred by section 48A(1) of the Pharmacy and Poisons Act 1979, makes the following Order: Citation 1 This Order may be cited as the Pharmacy and Poisons (Third and Fourth Schedule Amendment) Order 2017. Repeals and replaces the Third and Fourth Schedule of the Pharmacy and Poisons Act 1979 2 The Third and Fourth Schedules to the Pharmacy and Poisons Act 1979 are repealed and replaced with— “THIRD SCHEDULE (Sections 25(6); 27(1))) DRUGS OBTAINABLE ONLY ON PRESCRIPTION EXCEPT WHERE SPECIFIED IN THE FOURTH SCHEDULE (PART I AND PART II) Note: The following annotations used in this Schedule have the following meanings: md (maximum dose) i.e. the maximum quantity of the substance contained in the amount of a medicinal product which is recommended to be taken or administered at any one time. 1 PHARMACY AND POISONS (THIRD AND FOURTH SCHEDULE AMENDMENT) ORDER 2017 mdd (maximum daily dose) i.e. the maximum quantity of the substance that is contained in the amount of a medicinal product which is recommended to be taken or administered in any period of 24 hours. mg milligram ms (maximum strength) i.e. either or, if so specified, both of the following: (a) the maximum quantity of the substance by weight or volume that is contained in the dosage unit of a medicinal product; or (b) the maximum percentage of the substance contained in a medicinal product calculated in terms of w/w, w/v, v/w, or v/v, as appropriate.
    [Show full text]
  • Poisons Act.Fm
    LAWS OF BRUNEI CHAPTER 114 POISONS Enactment No. 13 of 1956 Amended by S 103/1958 Enactment No. 6 of 1967 S 101/1979 1984 Edition, Chapter 114 Amended by S 16/1996 S 28/2001 GN 273/2002 REVISED EDITION 2015 B.L.R.O. 1/2015 LAWS OF BRUNEI Poisons CAP. 114 1 LAWS OF BRUNEI REVISED EDITION 2015 CHAPTER 114 POISONS ARRANGEMENT OF SECTIONS Section 1. Citation. 2. Interpretation. 3. Description of poisons. 4. Licensing Officers. 5. General prohibition with respect to importation and sale of poisons. 6. Prohibitions and provisions relating to sale of poisons. 7. Exemptions in respect of medicines. 8. Exemptions in respect of sale. 9. Possession of poisons. 10. Issue of licences. 11. Different kinds of licence. 12. Licences to be numbered and registered. 13. Annual list to be published. 14. Forms of licence. 15. Search and search warrants. 16. Powers of exemption. 17. Penalties. B.L.R.O. 1/2015 LAWS OF BRUNEI 2 CAP. 114 Poisons 18. Jurisdiction. 19. Prosecutions. 20. Prohibition of sale to persons under 18. 21. Rules. SCHEDULE — POISONS LIST ____________________________ LAWS OF BRUNEI Poisons CAP. 114 3 POISONS ACT An Act to regulate the importation, possession, manufacture, compounding, storage, transport and sale of poisons Commencement: 1st January 1983 [S 61/1957] Citation. 1. This Act may be cited as the Poisons Act. Interpretation. 2. In this Act, unless the context otherwise requires — “dentist” means a dentist licensed under the Medical Practitioners and Dentists Act (Chapter 112) and includes a Government dentist; “export”, in relation
    [Show full text]
  • Pharmacy and Poisons Act 1979
    Q UO N T FA R U T A F E BERMUDA PHARMACY AND POISONS ACT 1979 1979 : 26 TABLE OF CONTENTS PART I PRELIMINARY 1 Short title 2 Interpretation PART II THE PHARMACY COUNCIL 3 The Pharmacy Council 4 Membership of the Council 4A Functions of the Council 4B Protection from personal liability 4C Annual Report 5 Proceedings of the Council, etc PART III REGISTRATION OF PHARMACISTS 6 Offence to practise pharmacy if not registered 7 Registration as a pharmacist 7A Re-registration as non-practising member 7AA Period of validity of registration 8 Code of Conduct 9 Pharmacy Profession Complaints Committee 10 Investigation of complaint by Committee 10A Inquiry into complaint by Council 10B Inquiry by Council of its own initiative 11 Surrender of registration 12 Restoration of name to register 1 PHARMACY AND POISONS ACT 1979 13 Proof of registration 14 Appeals 14A Fees 14B Amendment of Seventh Schedule 15 Regulations for this part PART IV REGISTRATION OF PHARMACIES 16 Register of pharmacies 17 Registration of premises as registered pharmacies 18 Unfit premises: new applications 19 Unfit premises: registered pharmacies 20 Appeals 21 When certificates of unfitness take effect 22 Regulations for this Part PART V CONTROL OF PRESCRIPTIONS AND IMPORTATION 23 Prescriptions to be in a certain form 23A Validity of a prescription 24 Supply by registered pharmacist of equivalent medicines 25 Restrictions on the importation of medicines 26 Declaration relating to imported medicines [repealed] PART VI CONTROL OF DRUGS 27 Certain substances to be sold on prescription
    [Show full text]
  • Partial Agreement in the Social and Public Health Field
    COUNCIL OF EUROPE COMMITTEE OF MINISTERS (PARTIAL AGREEMENT IN THE SOCIAL AND PUBLIC HEALTH FIELD) RESOLUTION AP (88) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION (Adopted by the Committee of Ministers on 22 September 1988 at the 419th meeting of the Ministers' Deputies, and superseding Resolution AP (82) 2) AND APPENDIX I Alphabetical list of medicines adopted by the Public Health Committee (Partial Agreement) updated to 1 July 1988 APPENDIX II Pharmaco-therapeutic classification of medicines appearing in the alphabetical list in Appendix I updated to 1 July 1988 RESOLUTION AP (88) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION (superseding Resolution AP (82) 2) (Adopted by the Committee of Ministers on 22 September 1988 at the 419th meeting of the Ministers' Deputies) The Representatives on the Committee of Ministers of Belgium, France, the Federal Republic of Germany, Italy, Luxembourg, the Netherlands and the United Kingdom of Great Britain and Northern Ireland, these states being parties to the Partial Agreement in the social and public health field, and the Representatives of Austria, Denmark, Ireland, Spain and Switzerland, states which have participated in the public health activities carried out within the above-mentioned Partial Agreement since 1 October 1974, 2 April 1968, 23 September 1969, 21 April 1988 and 5 May 1964, respectively, Considering that the aim of the Council of Europe is to achieve greater unity between its members and that this
    [Show full text]
  • ( 12 ) United States Patent
    US010131766B2 (12 ) United States Patent (10 ) Patent No. : US 10 , 131, 766 B2 Hazen et al. (45 ) Date of Patent: Nov . 20 , 2018 ( 54 ) UNSATURATED POLYESTER RESIN 6 ,619 ,886 B1 9 /2003 Harrington 6 ,692 , 802 B1 2 / 2004 Nava SYSTEM FOR CURED IN - PLACE PIPING 7 , 135 ,087 B2 11/ 2006 Blackmore et al. 7 ,799 ,228 B2 9 /2010 Bomak et al . (71 ) Applicant : Interplastic Corporation , Saint Paul, 8 , 047, 238 B2 11/ 2011 Wiessner et al . MN (US ) 8 ,053 ,031 B2 11/ 2011 Stanley et al. 8 ,092 ,689 B2 1 / 2012 Gosselin (72 ) Inventors : Benjamin R . Hazen , Roseville , MN 8 , 298 , 360 B2 10 / 2012 Da Silveira et al. 8 ,418 , 728 B1 4 / 2013 Kiest , Jr . (US ) ; David J . Herzog , Maple Grove , 8 ,586 ,653 B2 11 / 2013 Klopsch et al. MN (US ) ; Louis R . Ross, Cincinnati , 8 ,636 , 869 B2 1 / 2014 Wiessner et al . OH (US ) ; Joel R . Weber , Moundsview , 8 ,741 , 988 B2 6 /2014 Klopsch et al. MN (US ) 8 , 877 , 837 B2 11/ 2014 Yu et al. 9 ,068 , 045 B2 6 /2015 Nava et al. 9 ,074 , 040 B2 7 / 2015 Turshani et al. ( 73 ) Assignee : Interplastic Corporation , St. Paul , MN 9 , 150 , 709 B2 10 / 2015 Klopsch et al . (US ) 9 , 207 , 155 B1 12 / 2015 Allouche et al. 9 ,273 ,815 B2 3 / 2016 Gillanders et al. ( * ) Notice : Subject to any disclaimer, the term of this 9 , 371, 950 B2 6 / 2016 Hairston et al. patent is extended or adjusted under 35 9 , 550 , 933 B2 1 /2017 Chatterji et al .
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2011/0159073 A1 De Juan Et Al
    US 20110159073A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2011/0159073 A1 de Juan et al. (43) Pub. Date: Jun. 30, 2011 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA A6F 2/00 (2006.01) (US); Signe E. Varner, Los (52) U.S. Cl. ........................................................ 424/427 Angeles, CA (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Featured is a method for instilling one or more bioactive (21) Appl. No.: 12/981,038 agents into ocular tissue within an eye of a patient for the treatment of an ocular condition, the method comprising con (22) Filed: Dec. 29, 2010 currently using at least two of the following bioactive agent delivery methods (A)-(C): (A) implanting a Sustained release Related U.S. Application Data delivery device comprising one or more bioactive agents in a (63) Continuation of application No. 1 1/175,850, filed on posterior region of the eye so that it delivers the one or more Jul. 5, 2005, now abandoned. bioactive agents into the vitreous humor of the eye; (B) instill ing (e.g., injecting or implanting) one or more bioactive (60) Provisional application No. 60/585,236, filed on Jul. 2, agents Subretinally; and (C) instilling (e.g., injecting or deliv 2004, provisional application No. 60/669,701, filed on ering by ocular iontophoresis) one or more bioactive agents Apr. 8, 2005. into the vitreous humor of the eye. Patent Application Publication Jun. 30, 2011 Sheet 1 of 22 US 2011/O159073 A1 Patent Application Publication Jun.
    [Show full text]
  • Lääkealan Turvallisuus- Ja Kehittämiskeskuksen Päätös
    Lääkealan turvallisuus- ja kehittämiskeskuksen päätös N:o xxxx lääkeluettelosta Annettu Helsingissä xx päivänä maaliskuuta 2016 ————— Lääkealan turvallisuus- ja kehittämiskeskus on 10 päivänä huhtikuuta 1987 annetun lääke- lain (395/1987) 83 §:n nojalla päättänyt vahvistaa seuraavan lääkeluettelon: 1 § Lääkeaineet ovat valmisteessa suolamuodossa Luettelon tarkoitus teknisen käsiteltävyyden vuoksi. Lääkeaine ja sen suolamuoto ovat biologisesti samanarvoisia. Tämä päätös sisältää luettelon Suomessa lääk- Liitteen 1 A aineet ovat lääkeaineanalogeja ja keellisessä käytössä olevista aineista ja rohdoksis- prohormoneja. Kaikki liitteen 1 A aineet rinnaste- ta. Lääkeluettelo laaditaan ottaen huomioon lää- taan aina vaikutuksen perusteella ainoastaan lää- kelain 3 ja 5 §:n säännökset. kemääräyksellä toimitettaviin lääkkeisiin. Lääkkeellä tarkoitetaan valmistetta tai ainetta, jonka tarkoituksena on sisäisesti tai ulkoisesti 2 § käytettynä parantaa, lievittää tai ehkäistä sairautta Lääkkeitä ovat tai sen oireita ihmisessä tai eläimessä. Lääkkeeksi 1) tämän päätöksen liitteessä 1 luetellut aineet, katsotaan myös sisäisesti tai ulkoisesti käytettävä niiden suolat ja esterit; aine tai aineiden yhdistelmä, jota voidaan käyttää 2) rikoslain 44 luvun 16 §:n 1 momentissa tar- ihmisen tai eläimen elintoimintojen palauttami- koitetuista dopingaineista annetussa valtioneuvos- seksi, korjaamiseksi tai muuttamiseksi farmako- ton asetuksessa kulloinkin luetellut dopingaineet; logisen, immunologisen tai metabolisen vaikutuk- ja sen avulla taikka terveydentilan
    [Show full text]
  • Page 1 FINLANDS FÖRFATTNINGSSAMLING Utgiven I Helsingfors
    FINLANDS FÖRFATTNINGSSAMLING MuuMnrovvvvBeslutom läkemedelsförteckning asia av Säkerhets- och utvecklingscentret för läkemedelsområdet Utgiven i Helsingfors den 23 mars 2016 201/2016 Beslut av Säkerhets- och utvecklingscentret för läkemedelsområdet om läkemedelsförteckning Säkerhets- och utvecklingscentret för läkemedelsområdet har med stöd av 83 § i läke- medelslagen av den 10 april 1987 (395/1987) beslutat fastställa följande läkemedelsför- teckning: 1§ Förteckningens syfte Föreliggande beslut innehåller en förteckning över ämnen och droger som används medicinskt i Finland. Läkemedelsförteckningen upprättas med beaktande av bestämmel- serna i 3 och 5 § i läkemedelslagen. Med läkemedel avses ett preparat eller ämne vars ändamål är att vid invärtes eller ut- värtes bruk bota, lindra eller förebygga sjukdomar eller sjukdomssymtom hos människor eller djur. Som läkemedel betraktas också ett sådant ämne eller en sådan kombination av ämnen för invärtes eller utvärtes bruk som kan användas för att genom farmakologisk, im- munologisk eller metabolisk verkan återställa, korrigera eller modifiera fysiologiska funk- tioner eller utröna hälsotillståndet eller sjukdomsorsaker hos människor eller djur. Läkemedelsförteckningen är inte uttömmande. Till läkemedel räknas även sådana äm- nen och droger som inte nämns i denna förteckning men som uppfyller definitionen av lä- kemedel i läkemedelslagen. Utöver fastställande av läkemedelsförteckningen beslutar Säkerhets- och utvecklings- centret för läkemedelsområdet med stöd av 6 § i läkemedelslagen vid behov om ett ämne eller ett preparat ska betraktas som ett läkemedel. Centret beslutar separat i respektive fall om ett preparat som innehåller ett ämne i förteckningen ska betraktas som ett läkemedel med beaktande av produktens framställningssätt, sammansättning, dess farmakologiska egenskaper, hur det används, dess spridning, hur känt det är hos konsumenterna och de ris- ker som kan vara förenade med dess användning.
    [Show full text]
  • New Apis and Impurity Reference Standards 2015 Acecarbromal
    New APIs and impurity reference standards 2015 Code Product CAS No. CS Price Unit Acecarbromal O O O Br MM1724.00 Acecarbromal 77-66-7 A 50mg N N H H Acefylline O O OH N MM1727.00 Acefylline 652-37-9 A 250mg N O N N Acenocoumarol O O O N + O MM1205.00 Acenocoumarol 152-72-7 A 250mg OH O Acetaminosalol H N O O MM1609.00 Acetaminosalol 118-57-0 A 250mg O OH Acetophenazine Maleate O N N OH S N MM1725.00 Acetophenazine Maleate 5714-00-1 A 100mg OH OH O O 2 Adapalene Br MM0681.05 Methyl 6-Bromo-2-naphthoate 33626-98-1 A 100mg O O O Methyl 6-[3-(1-Adamantyl)-4-methoxyphenyl]-2-naphthoate MM0681.06 106685-41-0 A 100mg (Adapalene Methyl Ester) O O Adenine N H 2 H N MM1495.00 Adenine 73-24-5 A 250mg N N N Adrenaline Tartrate OH H MM0614.12 DL-Adrenaline Hydrochloride 329-63-5 A 250mg H O N HCl H O Visit us at www.lgcstandards.com New APIs and impurity reference standards 2015 Code Product CAS No. CS Price Unit Alanine N H Imp. B (EP): (2S)-2-Aminopentanedioic Acid (Glutamic 2 MM1333.00 56-86-0 A 250mg H O OH Acid) O O Ambutonium Bromide O N H2 Br MM1780.00 Ambutonium Bromide 115-51-5 A 100mg + N Amiloride Hydrochloride O Imp. A (EP): Methyl 3,5-Diamino-6- Cl N MM0560.01 1458-01-1 A 100mg O chloropyrazine-2-carboxylate H2 N N N H2 Aminotadalafil O H N H N 2 N N H MM1271.00 Aminotadalafil 385769-84-6 A 100mg O O O Amitriptyline Hydrochloride (10,11-Dihydro-5H-dibenzo[a,d]cyclohepten-5-ylidene) O MM0062.15 3707-33-3 A 100mg acetic Acid OH Amotriphene Hydrochloride O N MM3021.00 Amotriphene Hydrochloride 568-69-4 A 50mg HCl O O Aripiprazole N H Imp.
    [Show full text]
  • Ep 2401275 B1
    (19) TZZ Z_ _T (11) EP 2 401 275 B1 (12) EUROPEAN PATENT SPECIFICATION (45) Date of publication and mention (51) Int Cl.: C07D 471/04 (2006.01) C07D 519/00 (2006.01) of the grant of the patent: A61K 31/4375 (2006.01) A61P 11/00 (2006.01) 24.07.2013 Bulletin 2013/30 (86) International application number: (21) Application number: 10707251.4 PCT/EP2010/052343 (22) Date of filing: 24.02.2010 (87) International publication number: WO 2010/097410 (02.09.2010 Gazette 2010/35) (54) NAPHTHYRIDINE DERIVATIVES HAVING BRONCHODILATING ACTIVITY NAPHTHYRIDIN-DERIVATE MIT BRONCHENERWEITERNDER WIRKUNG DÉRIVÉS DE NAPHTHYRIDINE À ACTIVITÉ BRONCHODILATATOIRE (84) Designated Contracting States: • THORNQVIST-OLTNER, Viveca AT BE BG CH CY CZ DE DK EE ES FI FR GB GR S-261 40 Landskrona (SE) HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL • TOFTERED, Jörgen PT RO SE SI SK SM TR S-224 72 Lund (SE) • WENSBO, David (30) Priority: 24.02.2009 US 155027 P S-260 21 Billeberga (SE) 28.08.2009 SE 0950620 • DALENCE, Maria S-224 71 Lund (SE) (43) Date of publication of application: 04.01.2012 Bulletin 2012/01 (74) Representative: Ström & Gulliksson AB Box 4188 (73) Proprietor: Respiratorius AB 203 13 Malmö (SE) 22643 Lund (SE) (56) References cited: (72) Inventors: EP-A1- 1 669 348 US-A- 4 031 103 • JOHANSSON, Martin US-A- 5 753 666 S-216 22 Limhamn (SE) Note: Within nine months of the publication of the mention of the grant of the European patent in the European Patent Bulletin, any person may give notice to the European Patent Office of opposition to that patent, in accordance with the Implementing Regulations.
    [Show full text]
  • Medicines (Prescription Only) (Jersey) Order 1997
    MEDICINES (PRESCRIPTION ONLY) (JERSEY) ORDER 1997 Revised Edition 20.625.95 Showing the law as at 1 January 2019 This is a revised edition of the law Medicines (Prescription Only) (Jersey) Order 1997 Arrangement MEDICINES (PRESCRIPTION ONLY) (JERSEY) ORDER 1997 Arrangement Article 1 Interpretation ................................................................................................... 5 2 Prescription only medicines ............................................................................ 7 3 Medicinal products that are not prescription only medicines ......................... 8 4 New medicinal products ................................................................................. 9 5 Appropriate practitioner .................................................................................. 9 6 Conditions for prescriptions relating to sale and supply ................................. 9 6A Conditions for prescriptions – administration ............................................... 11 7 Exemption for highly diluted medicinal products ........................................ 11 8 Exemptions for specified categories of persons ............................................ 11 9 Exemption for emergency sale or supply...................................................... 12 10 Exemption for sale or supply in hospitals or the prison................................ 14 11 Exemption for authorised needle supply services ......................................... 14 12 Exemption for sale or supply in cases involving another’s default
    [Show full text]